Is CLLS or WVE more profitable?

Cellectis has a net margin of -89.51% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% WAVE Life Sciences -309.73% -50.36% -40.06%

Does the media favor CLLS or WVE?

In the previous week, WAVE Life Sciences had 14 more articles in the media than Cellectis. MarketBeat recorded 17 mentions for WAVE Life Sciences and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.19 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CLLS or SDGR more profitable?

Schrodinger has a net margin of -40.61% compared to Cellectis' net margin of -89.51%. Schrodinger's return on equity of -30.85% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% Schrodinger -40.61% -30.85% -15.32%

Does the media favor CLLS or SDGR?

In the previous week, Schrodinger had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Schrodinger and 3 mentions for Cellectis. Schrodinger's average media sentiment score of 0.75 beat Cellectis' score of 0.00 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CLLS or IMTX?

Cellectis has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 3.47 -$67.59M -$0.67 N/A Immatics $37.30M 31.90 -$222.26M -$1.99 N/A

Is CLLS or IMTX more profitable?

Cellectis has a net margin of -89.51% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% Immatics -572.35% -47.36% -39.35%

Does the media refer more to CLLS or IMTX?

In the previous week, Cellectis had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Cellectis and 2 mentions for Immatics. Immatics' average media sentiment score of 1.14 beat Cellectis' score of 0.00 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRVS or CLLS?

In the previous week, Corvus Pharmaceuticals had 6 more articles in the media than Cellectis. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 3 mentions for Cellectis. Corvus Pharmaceuticals' average media sentiment score of 1.22 beat Cellectis' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MGTX or CLLS more profitable?

Cellectis has a net margin of -89.51% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% N/A -54.96% Cellectis -89.51% -80.66% -20.51%

Does the media refer more to MGTX or CLLS?

In the previous week, MeiraGTx had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for MeiraGTx and 3 mentions for Cellectis. MeiraGTx's average media sentiment score of 0.68 beat Cellectis' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cellectis (CLLS) Competitors

$2.75 +0.00 (+0.15%)

As of 12:46 PM Eastern

Compare

CLLS vs. WVE, SDGR, IMTX, CRVS, and MGTX

Should you buy Cellectis stock or one of its competitors? MarketBeat compares Cellectis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectis include WAVE Life Sciences (WVE), Schrodinger (SDGR), Immatics (IMTX), Corvus Pharmaceuticals (CRVS), and MeiraGTx (MGTX).

How does Cellectis compare to WAVE Life Sciences?

Cellectis (NASDAQ:CLLS) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Cellectis has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 14 more articles in the media than Cellectis. MarketBeat recorded 17 mentions for WAVE Life Sciences and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.00 beat WAVE Life Sciences' score of -0.19 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cellectis has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A
WAVE Life Sciences	$42.73M	25.39	-$204.38M	-$1.09	N/A

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 154.18%. WAVE Life Sciences has a consensus price target of $22.76, indicating a potential upside of 313.53%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Cellectis has a net margin of -89.51% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cellectis and WAVE Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Cellectis compare to Schrodinger?

Cellectis (NASDAQ:CLLS) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Schrodinger has a net margin of -40.61% compared to Cellectis' net margin of -89.51%. Schrodinger's return on equity of -30.85% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Schrodinger	-40.61%	-30.85%	-15.32%

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Schrodinger had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Schrodinger and 3 mentions for Cellectis. Schrodinger's average media sentiment score of 0.75 beat Cellectis' score of 0.00 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis presently has a consensus target price of $7.00, suggesting a potential upside of 154.18%. Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 32.34%. Given Cellectis' stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectis is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cellectis has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A
Schrodinger	$254.91M	4.43	-$103.26M	-$1.41	N/A

Summary

Cellectis and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

How does Cellectis compare to Immatics?

Cellectis (NASDAQ:CLLS) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Cellectis has a net margin of -89.51% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Immatics	-572.35%	-47.36%	-39.35%

Cellectis currently has a consensus price target of $7.00, suggesting a potential upside of 154.18%. Immatics has a consensus price target of $20.80, suggesting a potential upside of 134.42%. Given Cellectis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

In the previous week, Cellectis had 1 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Cellectis and 2 mentions for Immatics. Immatics' average media sentiment score of 1.14 beat Cellectis' score of 0.00 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cellectis has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A
Immatics	$37.30M	31.90	-$222.26M	-$1.99	N/A

Summary

Cellectis beats Immatics on 12 of the 17 factors compared between the two stocks.

How does Cellectis compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 150.16%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 154.18%. Given Cellectis' higher possible upside, analysts clearly believe Cellectis is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Corvus Pharmaceuticals' return on equity of -38.92% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Cellectis	-89.51%	-80.66%	-20.51%

Corvus Pharmaceuticals has higher earnings, but lower revenue than Cellectis. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A

In the previous week, Corvus Pharmaceuticals had 6 more articles in the media than Cellectis. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 3 mentions for Cellectis. Corvus Pharmaceuticals' average media sentiment score of 1.22 beat Cellectis' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corvus Pharmaceuticals beats Cellectis on 9 of the 15 factors compared between the two stocks.

How does Cellectis compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.91, indicating that its stock price is 191% more volatile than the broader market.

Cellectis has a net margin of -89.51% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Cellectis	-89.51%	-80.66%	-20.51%

MeiraGTx presently has a consensus price target of $26.00, suggesting a potential upside of 122.41%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 154.18%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, MeiraGTx had 2 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for MeiraGTx and 3 mentions for Cellectis. MeiraGTx's average media sentiment score of 0.68 beat Cellectis' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectis has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	13.57	-$114.20M	-$1.48	N/A
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cellectis beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$276.34M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.11	7.38	282.16	25.05
Price / Sales	3.47	1,220.59	576.18	79.91
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.62	16.79	10.96	6.18
Net Income	-$67.59M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-4.71%	-0.84%	0.45%	0.71%
1 Month Performance	-16.55%	-7.59%	-4.26%	-3.75%
1 Year Performance	-6.64%	49.20%	63.09%	20.17%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	1.9151 of 5 stars	$2.75 +0.1%	$7.00 +154.2%	-6.8%	$276.34M	$79.59M	N/A	290	Gap Up
WVE WAVE Life Sciences	3.0384 of 5 stars	$5.86 -1.1%	$26.41 +351.1%	-36.2%	$1.13B	$42.73M	N/A	240	Earnings Report Analyst Forecast
SDGR Schrodinger	2.4026 of 5 stars	$15.22 -0.4%	$20.25 +33.0%	-22.5%	$1.12B	$254.91M	N/A	790	Upcoming Earnings
IMTX Immatics	2.5764 of 5 stars	$8.35 -3.3%	$20.80 +149.1%	+33.6%	$1.12B	$37.30M	N/A	260	Positive News
CRVS Corvus Pharmaceuticals	3.3131 of 5 stars	$13.07 +1.2%	$33.33 +155.0%	+223.4%	$1.10B	N/A	N/A	30	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. WVE, SDGR, IMTX, CRVS, and MGTX

How does Cellectis compare to WAVE Life Sciences?

Summary

How does Cellectis compare to Schrodinger?

Summary

How does Cellectis compare to Immatics?

Summary

How does Cellectis compare to Corvus Pharmaceuticals?

Summary

How does Cellectis compare to MeiraGTx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. WVE, SDGR, IMTX, CRVS, and MGTX

How does Cellectis compare to WAVE Life Sciences?

Which has more risk and volatility, CLLS or WVE?

Does the media favor CLLS or WVE?

Which has better valuation and earnings, CLLS or WVE?

Do analysts prefer CLLS or WVE?

Is CLLS or WVE more profitable?

Do insiders & institutionals have more ownership in CLLS or WVE?

Summary

How does Cellectis compare to Schrodinger?

Which has more volatility and risk, CLLS or SDGR?

Is CLLS or SDGR more profitable?

Do insiders and institutionals have more ownership in CLLS or SDGR?

Does the media favor CLLS or SDGR?

Do analysts prefer CLLS or SDGR?

Which has higher earnings & valuation, CLLS or SDGR?

Summary

How does Cellectis compare to Immatics?

Is CLLS or IMTX more profitable?

Do analysts prefer CLLS or IMTX?

Which has more risk & volatility, CLLS or IMTX?

Does the media refer more to CLLS or IMTX?

Do insiders & institutionals have more ownership in CLLS or IMTX?

Which has preferable valuation & earnings, CLLS or IMTX?

Summary

How does Cellectis compare to Corvus Pharmaceuticals?

Do analysts prefer CRVS or CLLS?

Which has more risk and volatility, CRVS or CLLS?

Do institutionals and insiders have more ownership in CRVS or CLLS?

Is CRVS or CLLS more profitable?

Which has stronger earnings and valuation, CRVS or CLLS?

Does the media refer more to CRVS or CLLS?

Summary

How does Cellectis compare to MeiraGTx?

Which has more volatility and risk, MGTX or CLLS?

Is MGTX or CLLS more profitable?

Do analysts rate MGTX or CLLS?

Does the media refer more to MGTX or CLLS?

Which has higher valuation and earnings, MGTX or CLLS?

Do institutionals & insiders have more ownership in MGTX or CLLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools